According to ABIRATERONE ACETATE TABLET Labeling Directions, the ABIRATERONE drug target CYP17 should be effectiveness-associated; and the ABIRATERONE drug target CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5, CYP17 and SULT2A1 should also be risk-associated. The investigators hope to discover the CYP17 SNP Genotypes which may be effectiveness-associated, and the CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5, CYP17 and SULT2A1 SNP Genotypes which may be risk-associated.